With clinical failures mounting and companies disinvesting, researchers are revising the cancer stem cell model.
This is a preview of subscription content, log in via an institution to check access.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Garber, K. Cancer stem cell pipeline flounders. Nat Rev Drug Discov 17, 771–773 (2018). https://doi.org/10.1038/nrd.2018.157
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.157
- Springer Nature Limited
This article is cited by
-
Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling
npj Precision Oncology (2024)
-
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
Breast Cancer Research and Treatment (2021)